Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
91 hedge funds and large institutions have $275M invested in Eiger BioPharmaceuticals, Inc. in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 23 reducing their positions, and 7 closing their positions.
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
59% more call options, than puts
Call options by funds: $290K | Put options by funds: $182K
52% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 23
44% more capital invested
Capital invested by funds: $191M → $275M (+$83.5M)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
8% more funds holding
Funds holding: 84 → 91 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Davenport & Co
Richmond,
Virginia
|
+$3.01M |
| 2 |
BlackRock
New York
|
+$1.28M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.04M |
| 4 |
Two Sigma Investments
New York
|
+$879K |
| 5 |
Two Sigma Advisers
New York
|
+$643K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$7.22M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$4.68M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.95M |
| 4 |
BC
Broadfin Capital
New York
|
-$1.55M |
| 5 |
TI
Telemetry Investments
New York
|
-$960K |
EIGR Hedge Fund Activity: Q4 2019 in Review
91 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q4 2019, worth a combined $275M — up 44% from $191M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new EIGR positions and 7 closed out — a net gain of 7 holders — while 35 added to existing stakes and 23 trimmed.
The largest buyer was Davenport & Co, opening a new position worth an estimated $3.01M. The largest seller was EcoR1 Capital, cutting an estimated $7.22M.
- 91 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q4 2019, up from 84 in Q3 2019.
- Funds reported $275M of Eiger BioPharmaceuticals, Inc. stock for Q4 2019, up 44% quarter-over-quarter.
- 14 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q4 2019 and 7 closed out, a net change of +7 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q4 2019 was Davenport & Co, an estimated $3.01M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q4 2019 was EcoR1 Capital, an estimated $7.22M sold.
Based on aggregated 13F filings for Q4 2019.